Ask AI
ProCE Banner Activity

My Thoughts on Novel and Investigational Therapies in MDS

Clinical Thought
In this commentary, Amer M. Zeidan, MBBS, reviews the latest novel and investigational treatments for patients with myelodysplastic syndromes.

Released: November 22, 2021

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Gilead Sciences, Inc.

Novartis Pharmaceuticals Corporation

Taiho Oncology Inc

Faculty Disclosure

Primary Author

Amer Zeidan, MBBS, MHS

Professor of Internal Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Assistant Medical Director, Hematology, Clinical Trails Office (CTO)
Director, Hematology Early Therapeutics Research
Director, Leukemia and Myeloid Malignancies Program
Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT)
Section of Hematology, Department of Internal Medicine, Yale School of Medicine
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Amer M. Zeidan, MBBS, has disclosed that he has received funds for research support from AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Incyte, Medimmune/AstraZeneca, Novartis, Otsuka Pfizer, Takeda, and Trovagene and consulting fees from Acceleron, Agios, Amgen, Aprea, Astellas, Astex, BeyondSpring, Boehringer Ingelheim, Cardiff Oncology, Cardinal Health, Celgene/Bristol-Myers Squibb, Daiichi Sankyo, Epizyme, Gilead Sciences, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, and Tyme.